Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
This study evaluated the effect of the cholecystokinin antagonist L-364,718 on exocrine secretion in canine pancreatic autografts with pancreaticocystostomies. Urinary (autograft) amylase (U/min) and bicarbonate (mmole/min) secretion, over a 6 hr interval, were determined in the basal state (Group A), after a bolus injection of 20 nmoles/kg of L-364,718 (Group B), during a continuous cholecystokinin octapeptide (OP-CCK) infusion at 125 ng/kg/hr either alone (Group C), with a bolus injection of 20 nmoles/kg (Group D), or 30 nmoles/kg (Group E), of L-364,718 1 hr before initiating OP-CCK, or 20 nmoles/kg of L-364,718 1 hr after initiating OP-CCK (Group F). L-364,718 had no effect on basal or OP-CCK-stimulated secretion of bicarbonate. Basal amylase secretion was decreased 1 hr after L-364,718 and remained significantly lower than controls throughout the study interval. When compared to Group C (280.3 +/- 48.6), OP-CCK-stimulated amylase secretion was significantly lower for the first hour after L-364,718 in both Group D (157 +/- 46.7) and Group E (31.9 +/- 11.6). In Group E, 2, 3, and 4 hr post-L-364,718 amylase releases were 60.2 +/- 19.7, 77.7 +/- 25.1, and 87.2 +/- 28.3 compared to 335.5 +/- 85.9, 291.0 +/- 21.8, and 289.9 +/- 45.7 in Group C indicating a sustained significant inhibition of stimulated autograft amylase secretion with the higher L-364,718 dosage. In Group F, no significant change in amylase secretion was demonstrated, indicating that L-364,718 must be administered prior to CCK stimulation to be effective. These studies demonstrate that L-364,718 has a dose dependent, inhibitory effect on basal, and OP-CCK-stimulated amylase secretion in a denervated autograft model. The therapeutic potential of L-364,718 and other CCK receptor antagonists in pancreatic transplantation warrants further study.
Garvin
P J
PJ
Department of Surgery, Surgical Research Institute, St. Louis University Health Science Center, Missouri 63110-0250, USA.
Niehoff
M L
ML
Burton
F R
FR
Dysarz
F A
FA
Meadow
R
R
Solomon
H
H
D000681:Amylases / Q000378:metabolism / Q000652:urine; D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D001639:Bicarbonates / Q000378:metabolism; D002766:Cholecystokinin / Q000037:antagonists & inhibitors*; D020109:Devazepide; D004285:Dogs; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D010179:Pancreas / Q000187:drug effects* / Q000378:metabolism; D016035:Pancreas Transplantation; D012844:Sincalide / Q000494:pharmacology; D013997:Time Factors
D001570:Benzodiazepinones; D001639:Bicarbonates; D006727:Hormone Antagonists; D002766:Cholecystokinin; D000681:Amylases; D020109:Devazepide; D012844:Sincalide